AVGR - Avinger, Inc.
| Previous Close | 1.11 |
| Open | 1.20 |
| Bid | 1.05 x 2900 |
| Ask | 1.35 x 2200 |
| Day's Range | 1.11 - 1.20 |
| 52 Week Range | 0.95 - 16.40 |
| Volume | 417,816 |
| Avg. Volume | 260,655 |
| Market Cap | 13.054M |
| Beta (3Y Monthly) | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -17.05 |
| Earnings Date | May 2, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.25 |
- ACCESSWIRE•yesterday
Avinger Receives CE Marking Approval for Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
REDWOOD CITY, CA / ACCESSWIRE / October 18, 2018 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval of Pantheris SV (Small Vessel), a product line extension of the Lumivascular atherectomy system. CE Marking allows for distribution of Pantheris SV in the European Union (EU) and certain other countries that recognize the CE Marking. Pantheris SV is not available commercially in the United States at this time.
- ACCESSWIRE•last month
Avinger Announces Successful Treatment of 200th Patient with Next-Generation Pantheris Device
REDWOOD CITY, CA / ACCESSWIRE / September 5, 2018 / Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 35 sites globally have successfully treated over 200 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD). The next-generation Pantheris was launched on a limited basis in the U.S. following receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in late May 2018. Clinical results with the next-generation Pantheris across a spectrum of lesions and clinical situations have remained consistently positive and in-line with the early outcomes reported in late June and on the Company's earnings conference call in August 2018.
- GlobeNewswire•2 months ago
Avinger Announces 510(k) Filing of Pantheris Small Vessel Device
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food & Drug Administration (FDA) for the Pantheris SV (Small Vessel) Lumivascular atherectomy system. Pantheris SV is a line extension of the Pantheris family of catheters, the first and only image-guided atherectomy devices for the treatment of PAD. Designed with a lower profile and longer length, Pantheris SV is intended to expand the number of addressable procedures for Pantheris by allowing physicians to target lesions in smaller diameter vessels and more distal regions of the vasculature.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AVGR earnings conference call or presentation 13-Aug-18 9:00pm GMT
Q2 2018 Avinger Inc Earnings Call
- GlobeNewswire•2 months ago
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectomy System
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,052,125, titled “Atherectomy Catheter With Laterally-Displaceable Tip,” on August 21, 2018. This is the fifth patent issued by the USPTO with claims related to Avinger’s Pantheris image-guided atherectomy system.
- GlobeNewswire•2 months ago
Avinger Announces Participation in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 28, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today announced that management of Avinger will present at the following ...
- GlobeNewswire•2 months ago
Avinger Completes Enrollment in SCAN Clinical Study
Avinger, Inc. (AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherence tomography (OCT) with intravascular ultrasound (IVUS) as a diagnostic imaging tool in the peripheral arteries. Avinger’s proprietary Lumivascular technology utilizes OCT to provide real-time vascular imaging for the diagnosis and treatment of peripheral artery disease.
- Associated Press•2 months ago
Avinger: 2Q Earnings Snapshot
On a per-share basis, the Redwood City, California-based company said it had a loss of 98 cents. The medical device maker posted revenue of $2.1 million in the period. In the final minutes of trading on ...
- GlobeNewswire•2 months ago
Avinger Announces Second Quarter 2018 Financial Results
REDWOOD CITY, Calif., Aug. 13, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, today reported results for the second quarter ended June 30, 2018.. Second ...
- ACCESSWIRE•2 months ago
Avinger, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 13, 2018 / Avinger, Inc. (NASDAQ: AVGR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 13, 2018 at 5:00 PM Eastern Time. To ...
- GlobeNewswire•2 months ago
Avinger to Report Second Quarter 2018 Results on Monday, August 13, 2018
REDWOOD CITY, Calif., Aug. 06, 2018-- Avinger, Inc., a leading developer of innovative treatments for peripheral artery disease, will announce its second quarter 2018 results for the period ended June ...
- ACCESSWIRE•3 months ago
Complimentary Technical Snapshots on PAVmed and Three More Medical Equipment Stocks
WallStEquities.com revisits the Medical Appliances and Equipment space, which is engaged in the manufacture of medical instruments such as dental and surgical appliances. Under evaluation this morning are these four stocks: EDAP TMS S.A. (NASDAQ: EDAP), PAVmed Inc. (NASDAQ: PAVM), Amedica Corp. (NASDAQ: AMDA), and Avinger Inc. (NASDAQ: AVGR).
- Market Realist•4 months ago
Avinger Stock Up 16% on Pantheris Device US Launch
Yesterday, Avinger (AVGR) stock rose ~16% as the company announced the successful treatment of its first patients with its next-gen Pantheris device for PAD (peripheral artery disease). The successful treatment of these patients with the Pantheris device lays the foundation for the device’s expanded US launch. Avinger has achieved one of its key milestones, as the image above shows.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Achaogen and Avinger
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Shares of Achaogen were plummeting in Tuesday trading after the FDA cleared the way for its Zemdri as a new treatment for patients with cUTI, including pyelonephritis, due to certain Enterobacteriaceae but issued a complete response letter for the drug as a potential treatment option for blood stream infection. Shares of Avinger were soaring after the company announced a positive initial case experience using the company's next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).
- ACCESSWIRE•4 months ago
Initiating Free Research Reports on Avinger and Three Other Medical Equipment Equities
Pre-market today, WallStEquities.com scans the following Medical Appliances and Equipment stocks: Amedica Corp. (NASDAQ: AMDA), Avinger Inc. (NASDAQ: AVGR), AxoGen Inc. (NASDAQ: AXGN), and Corindus Vascular Robotics Inc. (NYSE AMER: CVRS).
- Simply Wall St.•4 months ago
Avinger Inc (NASDAQ:AVGR): Is Breakeven Near?
Avinger Inc’s (NASDAQ:AVGR): Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) inRead More...
- Simply Wall St.•4 months ago
Loss-Making Avinger Inc (NASDAQ:AVGR) Expected To Breakeven
Avinger Inc’s (NASDAQ:AVGR): Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) inRead More...
